At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
HM15211 or Placebobiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211(Efocipegtrutide) in Healthy Obese Subjects
In Brief
A Phase 1 clinical trial evaluating HM15211 or Placebo for Obesity. Completed, enrolled 41 participants across 1 site.
Detailed Summary
Single ascending dose of HM15211 in healthy obese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 2017
Enrollment StartApr 2018
Primary CompletionSep 2018
TodayJul 2026
First PostedDec 15, 2017
Enrollment StartApr 4, 2018
Primary CompletionSep 14, 2018
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 8.5 years ago
Interventions
HM15211 or Placebobiological
Long-acting tri-agonist